Clinical Trial Detail

NCT ID NCT01139723
Title A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech
Indications

Advanced Solid Tumor

Therapies

Bevacizumab

MINT1526A

Age Groups: adult

No variant requirements are available.